Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. The company offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. It operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is headquartered in Chaozhou, China.
Research context
Guangdong Hybribio Biotech Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Guangdong Hybribio Biotech Co.,Ltd is currently in a long term downtrend where the price is trading 1.1% below its 200 day moving average.
From a valuation standpoint, the stock is 32.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.5.
Guangdong Hybribio Biotech Co.,Ltd's total revenue rose by 94.3% to $411M since the same quarter in the previous year.
Its net income has increased by 241.2% to $144M since the same quarter in the previous year.
Finally, its free cash flow grew by 618.9% to $79M since the same quarter in the previous year.
Based on the above factors, Guangdong Hybribio Biotech Co.,Ltd gets an overall score of 4/5.